Table 2.

Clinical data from patients treated with bisphosphonates

Fracture status	Patient	Age (years)	Sex	Side	Alendronate	Duration (years)	Other bisphosphonates	Duration (years)	Followup (months)	Additional surgery
Stress fracture treated prophylactically	1	76	Female	Left	Yes	3+	No		67	No
	2	76	Female	Right	Yes	3+	No		84	No
	3	74	Female	Right	Yes	3	No		72	No
	4	76	Female	Right	Yes	7	No		59	No
	4	76	Female	Left	Yes	7	No		59	No
	5	65	Female	Right	Yes	9+	No		42	No
	6	79	Male	Right	No		Zoledronic acid, pamidronate	10	25	No
	7	53	Female	Left	Yes	5+	Risedronate	1+	10	No
	8	90	Female	Right	Yes	9	Ibandronate	1+	20	No
	9	61	Female	Left	Yes	3+	Zoledronic acid	1.5	20	No
	9	61	Female	Right	Yes	3+	Zoledronic acid	1.5	19	No
	10	69	Female	Right	Yes	8.5	No		18	No
	11	64	Female	Right	Yes	4+	No		80	No
	12	84	Female	Left	No		Risedronate	6	10	No
Completed fracture after radiographic studies	3	74	Female	Left	Yes	3	No		74	No
	7	51	Female	Right	Yes	4	Risedronate	1+	28	Yes*
	10	69	Female	Left	Yes	8.5	No		18	No
	13	72	Female	Right	Yes	4+	Zoledronic acid	1	9	No
	14	66	Female	Left	Yes	10+	No		16	No
	14	66	Female	Right	Yes	9+	No		29	No
	16	66	Female	Right	Yes	7	No		73	Yes†
Completed fracture before any radiographic studies	5	60	Female	Left	Yes	4+	No		112	Yes‡
	15	65	Female	Left	Yes	10	No		11	Yes§
	16	65	Female	Left	Yes	6	No		89	Yes∥

* Dynamized at 6 months; revised at 10 months for broken intramedullary nail; ^†nonunion requiring revision reconstruction nail at 15 months; ^‡dynamized at 3 months; ^§dynamized at 7 months; ^∥nonunion requiring revision reconstruction nail at 18 months.